Primorigen Biosciences gets grant for stem cell work

Primorigen Biosciences, Madison, has received a $1.2 million Phase 2 Small Business Innovation Research grant from the National Institutes of Health. The funds will speed the company’s work on a new, cost-effective system for producing stem cells and transforming them into specific cell lines, such as blood, liver and neural cells, said chief executive Chuck Oehler. Primorigen will collaborate on the project with EMD Millipore Corp., a division of Merck. Read more